Trial Profile
Pharmacokinetics hormone response and safety profile of multiple ascending doses of elagolix in healthy premenopausal women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2017
Price :
$35
*
At a glance
- Drugs Elagolix (Primary)
- Indications Endometriosis; Pelvic pain; Uterine leiomyoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors AbbVie
- 30 Mar 2017 New trial record
- 16 Feb 2017 Results published in the Journal of Clinical Endocrinology and Metabolism